Vitamin combination promotes ex vivo expansion of NK-92 cells by reprogramming glucose metabolism

Abstract

Robust ex vivo expansion of NK-92 cells is essential for clinical immunotherapy. The vitamin B group is critical for the expansion and function of immune cells. This study optimized a vitamin combination by response surface methodology based on an in-house designed chemically defined serum-free medium EM. The serum-free medium EM-V4 with an optimal vitamin combination favoured ex vivo expansion of NK-92 cells. The characteristics of glucose metabolism of NK-92 cells in EM-V4 and the relationships between cell expansion and metabolism were investigated. NK-92 cells in EM-V4 underwent metabolic reprogramming. An elevated ratio of glucose-6-phosphate dehydrogenase/phosphofructokinase (G6PDH/PFK) indicated that NK-92 cells shifted towards the pentose phosphate pathway (PPP). An increase in the ratio of pyruvate dehydrogenase/lactate dehydrogenase (PDH/LDH) suggested that the cells shifted towards the Krebs (TCA) cycle, i.e., from glycolysis to aerobic metabolism. The enhanced ratio of oxygen consumption rate/extracellular acidification rate (OCR/ECAR) indicated that NK-92 cells were more reliant on mitochondrial respiration than on glycolysis. This shift provided more intermediate metabolites and energy for biosynthesis. Thus, EM-V4 accelerated biomass accumulation and energy production to promote NK-92 cell expansion by regulating the metabolic distribution. Our results provide valuable insight for the large-scale ex vivo expansion of clinically available NK-92 cells.

Keywords

NK-92 cells / Ex vivo expansion / Response surface methodology / Vitamin concentration optimization / Glucose metabolism

References

[1] Assmann N, O'Brien KL, Donnelly RP, Dyck L, Zaiatz-Bittencourt V, Loftus RM, Heinrich P, Oefner PJ, Lynch L, Gardiner CM. Srebp-controlled glucose metabolism is essential for NK cell functional responses. Nat Immunol, 2017, 18: 1197-1206.

[2] Bachanova V, McKenna DH, Luo X, Defor TE, Cooley S, Warlick E, Weisdorf DJ, Brachya G, Peled T, Miller JS. First-in-human phase I study of nicotinamide-expanded related donor natural killer cells for the treatment of relapsed/refractory non-hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant, 2019, 25: S175-S176.

[3] Bizukojc M, Pawlowska B, Ledakowicz S. Supplementation of the cultivation media with B-group vitamins enhances lovastatin biosynthesis by Aspergillus terreus. J Biotechnol, 2007, 127: 258-268.

[4] Burton LE, Wells WW. Myo-inositol metabolism during lactation and development in the rat. The prevention of lactation-induced fatty liver by dietary myo-inositol. J Nutr, 1976, 106: 1617-1628.

[5] Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol, 2016, 16: 112-123.

[6] Chiossone L, Dumas P-Y, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol, 2018, 18: 671-688.

[7] Chrobok M, Dahlberg CI, Sayitoglu EC, Beljanski V, Nahi H, Gilljam M, Stellan B, Sutlu T, Duru AD, Alici E. Functional assessment for clinical use of serum-free adapted NK-92 cells. Cancers, 2019, 11: 69.

[8] Colazingari S, Fiorenza MT, Carlomagno G, Najjar R, Bevilacqua A. Improvement of mouse embryo quality by myo-inositol supplementation of IVF media. J Assist Reprod Genet, 2014, 31: 463-469.

[9] Depeint F, Bruce WR, Shangari N, Mehta R, O’Brien PJ. Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism. Chem Biol Interact, 2006, 163: 94-112.

[10] Gardiner CM. NK cell metabolism. J Leukoc Biol, 2019, 105: 1235-1242.

[11] Gong J-H, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia, 1994, 8: 652-658.

[12] Greiner EF, Guppy M, Brand K. Glucose is essential for proliferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production. J Biol Chem, 1994, 269: 31484-31490.

[13] Grudzien M, Rapak A. Effect of natural compounds on NK cell activation. J Immunol Res, 2018

[14] Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol, 2016, 17: 1025-1036.

[15] Han H-S, Kang G, Kim JS, Choi BH, Koo S-H. Regulation of glucose metabolism from a liver-centric perspective. Exp Mol Med, 2016, 48: e218-e218.

[16] Hodge DL, Schill WB, Wang JM, Blanca I, Reynolds DA, Ortaldo JR, Young HA. IL-2 and IL-12 alter NK cell responsiveness to IFN-γ-inducible protein 10 by down-regulating CXCR3 expression. J Immunol, 2002, 168: 6090-6098.

[17] Horwitz ME, Chao NJ, Rizzieri DA, Long GD, Sullivan KM, Gasparetto C, Chute JP, Morris A, McDonald C, Waters-Pick B. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Investig, 2014, 124: 3121-3128.

[18] Inoue K, Ogonuki N, Yamamoto Y, Noguchi Y, Takeiri S, Nakata K, Miki H, Kurome M, Nagashima H, Ogura A. Improved postimplantation development of rabbit nuclear transfer embryos by activation with inositol 1, 4, 5-trisphosphate. Cloning Stem Cells, 2002, 4: 311-317.

[19] Jung J, Zeng H, Horng T. Metabolism as a guiding force for immunity. Nat Cell Biol, 2019, 21: 85-93.

[20] Khorraminejad-Shirazi M, Sani M, Talaei-Khozani T, Dorvash M, Mirzaei M, Faghihi MA, Monabati A, Attar A. AICAR and nicotinamide treatment synergistically augment the proliferation and attenuate senescence-associated changes in mesenchymal stromal cells. Stem Cell Res Ther, 2020, 11: 1-17.

[21] Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy–advantages of the NK-92 cell line over blood NK cells. Front Immunol, 2016

[22] MacIver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL, Rathmell JC. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol, 2008, 84: 949-957.

[23] Mazur-Bialy A, Pochec E, Plytycz B. Immunomodulatory effect of riboflavin deficiency and enrichment-reversible pathological response versus silencing of inflammatory activation. J Physiol Pharmacol, 2015, 66: 793-802.

[24] Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Cantó C, Mottis A, Jo Y-S, Viswanathan M, Schoonjans K. The NAD+/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell, 2013, 154: 430-441.

[25] O’Brien KL, Finlay DK. Immunometabolism and natural killer cell responses. Nat Rev Immunol, 2019, 19: 282-290.

[26] Pearce EL, Poffenberger MC, Chang C-H, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science, 2013, 342: 1242454.

[27] Pockley AG, Vaupel P, Multhoff G. NK cell-based therapeutics for lung cancer. Expert Opin Biol Ther, 2020, 20: 23-33.

[28] Poznanski SM, Barra NG, Ashkar AA, Schertzer JD. Immunometabolism of T cells and NK cells: metabolic control of effector and regulatory function. Inflamm Res, 2018, 67: 813-828.

[29] Romanski A, Uherek C, Bug G, Seifried E, Klingemann H, Wels WS, Ottmann OG, Tonn T. CD 19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med, 2016, 20: 1287-1294.

[30] Schnellbaecher A, Binder D, Bellmaine S, Zimmer A. Vitamins in cell culture media: Stability and stabilization strategies. Biotechnol Bioeng, 2019, 116: 1537-1555.

[31] Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T. NK-92: an ‘off-the-shelf therapeutic’for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother, 2016, 65: 485-492.

[32] Suwannasom N, Kao I, Pruß A, Georgieva R, Bäumler H. Riboflavin: The health benefits of a forgotten natural vitamin. Int J Mol Sci, 2020, 21: 950.

[33] Tam Y, Martinson J, Doligosa K, Klingemann H. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy, 2003, 5: 259-272.

[34] Tan CL, Chin T, Tan CYR, Rovito HA, Quek LS, Oblong JE, Bellanger S. Nicotinamide metabolism modulates the proliferation/differentiation balance and senescence of human primary keratinocytes. J Investig Dermatol, 2019, 139(1638–1647

[35] Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, Yin J, You F, Zhu M, Shen W. Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res, 2018, 8: 1899-1899.

[36] Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol, 2008, 9: 503-510.

[37] Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene, 2008, 27: 5932-5943.

[38] Williams B, Routy B, Wang X-H, Chaboureau A, Viswanathan S, Keating A. NK-92 Therapy is well tolerated, has minimal toxicity and shows efficacy in a phase I trial of patients with relapsed/refractory hematological malignancies relapsing after autologous stem cell transplantation. Blood, 2015, 126: 4297.

[39] Xin Z, Pu L, Gao W, Wang Y, Wei J, Shi T, Yao Z, Guo C. Riboflavin deficiency induces a significant change in proteomic profiles in HepG2 cells. Sci Rep, 2017, 7: 1-10.

[40] Zhang H, Ryu D, Wu Y, Gariani K, Wang X, Luan P, D’Amico D, Ropelle ER, Lutolf MP, Aebersold R. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science, 2016, 352: 1436-1443.

[41] Zhang W, Cai H, Tan W-S. Dynamic suspension culture improves ex vivo expansion of cytokine-induced killer cells by upregulating cell activation and glucose consumption rate. J Biotechnol, 2018, 287: 8-17.

[42] Zhang W, Huang H, Cai H, Tan WS. Enhanced metabolic activities for ATP production and elevated metabolic flux via pentose phosphate pathway contribute for better CIK cells expansion. Cell Prolif, 2019, 52.

[43] Zhou M, Crawford Y, Ng D, Tung J, Pynn AF, Meier A, Yuk IH, Vijayasankaran N, Leach K, Joly J. Decreasing lactate level and increasing antibody production in Chinese Hamster Ovary cells (CHO) by reducing the expression of lactate dehydrogenase and pyruvate dehydrogenase kinases. J Biotechnol, 2011, 153: 27-34.